Márta 2024: Tá faomhadh tugtha ag an Riarachán Bia agus Drugaí chun nivolumab (Opdivo, Bristol-Myers Squibb Company) a úsáid i gcomhar le cisplatin agus gemcitabine mar chóireáil tosaigh d’othair aosacha a bhfuil unres orthu.
Feb 2024: The Food and Drug Administration has sped up the approval process for two drugs, enfortumab vedotin-ejfv (Padcev, Astellas Pharma) and pembrolizumab (Keytruda, Merck). These drugs are meant to treat people with locally ..
Lúnasa 2021: Tá Nivolumab (Opdivo, Bristol-Myers Squibb Co).
August 2021: Enfortumab vedotin-ejfv (Padcev, Astellas Pharma US, Inc.), a Nectin-4-directed antibody and microtubule inhibitor combination, has been approved by the Food and Drug Administration for adult patients with locally adv..
Lúnasa 2021: Thug an Riarachán Bia agus Drugaí cead luathaithe do Sacituzumab govitecan (Trodelvy, Immunomedics Inc.) d’othair a raibh ailse úiréiteach metastatach chun cinn áitiúil nó metastatach (mUC) a bhí faighte acu roimhe seo.